Abstracts tagged "systemic lupus erythematosus (SLE) and clinical trials"

Abstract Number: 2546 • 2019 ACR/ARP Annual Meeting
Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial
Anca Askanase¹, Amit Saxena ², Aikaterini Thanou ³, Cristina Arriens ⁴, Debra J. Zack ⁵ and Joan Merrill ⁶, ¹Columbia University, New York, ²New York University Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Xencor, Inc., San Diego, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Measuring improvement or worsening is problematic in lupus trials. The British Isles Lupus Assessment Group (BILAG) index often fails to capture sustained decrease in…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Abstracts tagged "systemic lupus erythematosus (SLE) and clinical trials"

Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial